Print

Infinity Pharmaceuticals Inc. (INFI) to Present IPI-145 Phase 1 Clinical Data at American Society of Hematology  
11/5/2012 9:47:52 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that data from its ongoing Phase 1 trial of IPI-145, the company’s potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma will be presented at the 54th American Society of Hematology (ASH) Annual Meeting and Exhibition. The Phase 1 trial of IPI-145 is an open-label, dose-escalation study evaluating IPI-145 in patients with advanced hematologic malignancies. The presentation will include data describing the safety, pharmacokinetics and clinical activity of IPI-145. The ASH meeting is being held in Atlanta, Georgia, from December 8 – 11, 2012.
//-->